Skip to main content

August 2013 Vol 6, No 6 Special Issue

Practice Management
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Caroline Helwick
Read More
Lung Cancer, Oncology
Crizotinib Superior to Standard Chemotherapy in ALK-Positive Lung Cancer
Read More
FDA Approvals
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Read More
Perspectives
Cancer Care in 2013: Hope, Reality, and a Call to Action
Gary M. Owens, MD
Read More
Experts Debate Value of Bevacizumab in Newly Diagnosed Glioblastoma
Audrey Andrews
Read More
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
Read More
Sorafenib Effective in Metastatic Differentiated Thyroid Cancer
Audrey Andrews
Read More
Prostate Cancer
New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status
Wayne Kuznar
Read More
Prostate Cancer
Lack of Knowledge Prevents Men with Early-Stage Prostate Cancer from Choosing Active Surveillance
Wayne Kuznar
Read More
Breast Cancer, Oncology
New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer
Wayne Kuznar
Read More
Page 1 of 4
Results 1 - 10 of 34